Research programme: gliadin protein therapeutics - Diamyd Medical
Latest Information Update: 12 Oct 2015
At a glance
- Originator Unknown
- Developer Diamyd Medical AB
- Class Proteins
- Mechanism of Action Gliadin modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Coeliac disease; Type 1 diabetes mellitus